

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Fisher
Serial No. : 09/933,115 Examiner: Angell, Jon E
Filed : August 20, 2001 Group Art Unit: 1635
For : COMBINATORIAL METHODS FOR INDUCING CANCER CELL
DEATH

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231

April 20, 2005

Date of Deposit

Lisa B. Kole

Attorney Name


Signature

35,225

PTO Registration No.

April 20, 2005

Date of Signature

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Applicants wish to make of record the following references:

1. Cunningham et al., "Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study" Mol Ther. 2005 11(1):149-159.


2. Tong et al., "Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients" Mol Ther. 2005 11(1):160-172.
3. Ramesh et al., "Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery" DNA Cell Biol. 2004 23(12):850-857.
4. Sarkar et al., 2002. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK Proc. Natl Acad Sci USA 99(15):10054-10059.
5. International Patent Application No. PCT/US99/05996, Publication No. WO 99/47709, by Maki et al, published in English on September 23,, 1999. Methods for identifying anticancer agents.

References 1-3 contained in the Supplemental Information Disclosure Statement and PTO form 1449 are cited in the response mailed April 20, 2005 to the Office Action dated October 20, 2004, and copies of those references are attached thereto as Exhibits 1-3. References 4 and 5 contained in the Supplemental Information Disclosure Statement and PTO form 1449 was first cited in an International Search Report, enclosed herewith and mailed on September 24, 2004, for International Patent Application No. PCT/US03/21237, filed on July 3, 2003 by Fisher et al., Titled: "Methods for identifying modulators of MDA-7 mediated apoptosis" and published under International Publication No. WO 2004/005481.

Applicants respectfully request that the Examiner review the foregoing reference and that it be made of record in the file history of the above-mentioned application. Identification of the above-listed reference is not to be construed as an admission of the Applicants or the attorneys of the Applicants that this reference is available as "prior art" against the subject application.

Applicants believe that no fee is due in the submission of this supplemental information disclosure statement. If however the Commissioner deems it necessary, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4377. Two copies of this communication are enclosed.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Lisa B. Kole", written over a horizontal line.

Lisa B. Kole,
Patent Office Reg. No. 35,225

Attorney for Applicants
(212) 408-2628

Enclosures

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466(070050.1618)	Serial No. 09/933,115
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher	
	Filing Date August 10, 2001	Group 1635
	Examiner Angell, Jon E	

U.S. PATENT DOCUMENTS

Exam. Init.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Appro.

FOREIGN PATENT DOCUMENTS

No.	Document No.	Date	Country	Class	Subclass	Translation Yes No
5	WO 99/47709	Sept. 23, 1999	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

No.	
1	Cunningham et al., "Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study" Mol Ther. 2005 11(1):149-159.
2	Tong et al., "Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients" Mol Ther. 2005 11(1):160-172.

NY02:517797

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. A34466(070050.1618)	Serial No. 09/933,115
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant Fisher	
	Filing Date August 10, 2001	Group 1635
	Examiner Angell, Jon E	

	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	3	Ramesh et al., "Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery" DNA Cell Biol. 2004 23(12):850-857.
	4	Sarkar et al., 2002. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK Proc. Natl Acad Sci USA 99(15):10054-10059.

NY02:517797

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.